Results 261 to 270 of about 32,363 (292)
Some of the next articles are maybe not open access.

HFrEF pharmacological treatment: ivabradine

2018
Ivabradine slows down the heart rate through a blockade of the funny current channels in the sinoatrial node cells. The efficacy of the drug was tested in a large outcome clinical trial in stable chronic heart failure with reduced ejection fraction, in sinus rhythm, on a contemporary background therapy including beta blockers.
openaire   +2 more sources

Vericiguat in HFrEF

JACC: Heart Failure, 2023
openaire   +1 more source

Neue Therapiekonzepte der HfrEF

Kardiologie up2date, 2021
Amr Abdin, Jan Wintrich, Michael Böhm
openaire   +1 more source

Co-morbidity (HFrEF and HFpEF): hypertension

2018
Hypertensive heart disease is a major cause of heart failure (HF) and mortality. Hypertension precedes HF occurrence in 75% of cases, and carries a sixfold increase in HF risk as compared to non-hypertensive individuals. Most importantly, a minority of patients survive 5 years after the onset of hypertensive HF.
Francesco Paneni, Massimo Volpe
openaire   +2 more sources

Comparison Chart: Some Drugs for HFrEF

The Medical Letter on Drugs and Therapeutics
Comparison Chart: Some Drugs for ...
openaire   +2 more sources

HFrEF pharmacological treatment: beta blockers

2018
By incremental steps over several decades of research, beta blockers have evolved ‘from bench to bedside’, emerging as a keystone of modern optimal pharmacotherapy for heart failure. This chapter starts by detailing the story of their development, focusing on the randomized trials that established their clinical efficacy in reducing hospitalization and
openaire   +1 more source

HFpEF vs. HFrEF: can microRNAs advance the diagnosis?

European Journal of Heart Failure, 2015
Schmitter, Daniela   +2 more
openaire   +3 more sources

URBAN VS. RURAL HFREF OUTCOMES

Journal of the American College of Cardiology, 2022
Lauren Gray Gilstrap   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy